Johnson & Johnson $JNJ Stake Lessened by MJP Associates Inc. ADV

MJP Associates Inc. ADV decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,588 shares of the company’s stock after selling 406 shares during the quarter. MJP Associates Inc. ADV’s holdings in Johnson & Johnson were worth $854,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Cetera Investment Advisers boosted its position in Johnson & Johnson by 0.8% during the 2nd quarter. Cetera Investment Advisers now owns 714,423 shares of the company’s stock worth $109,128,000 after acquiring an additional 5,450 shares during the period. Fusion Capital LLC lifted its position in shares of Johnson & Johnson by 3.2% in the second quarter. Fusion Capital LLC now owns 40,755 shares of the company’s stock worth $6,225,000 after purchasing an additional 1,280 shares in the last quarter. WealthShield Partners LLC boosted its holdings in shares of Johnson & Johnson by 6.1% during the second quarter. WealthShield Partners LLC now owns 6,346 shares of the company’s stock worth $969,000 after purchasing an additional 366 shares during the period. OmniStar Financial Group Inc. grew its position in Johnson & Johnson by 100.7% during the second quarter. OmniStar Financial Group Inc. now owns 23,595 shares of the company’s stock valued at $3,604,000 after purchasing an additional 11,837 shares in the last quarter. Finally, Meridian Wealth Management LLC increased its stake in Johnson & Johnson by 0.4% in the 2nd quarter. Meridian Wealth Management LLC now owns 43,575 shares of the company’s stock valued at $6,657,000 after buying an additional 176 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research report on Monday, October 20th. Raymond James Financial lifted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Finally, Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $196.00 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $197.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $472.22 billion, a P/E ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38. The company’s 50-day simple moving average is $185.81 and its 200 day simple moving average is $169.94.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.